Welcome to our dedicated page for VALEO PHARMA news (Ticker: VPHIF), a resource for investors and traders seeking the latest updates and insights on VALEO PHARMA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect VALEO PHARMA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of VALEO PHARMA's position in the market.
Valeo Pharma has announced a Commercial Services Agreement with Veru for the distribution of sabizabulin, which demonstrated a 55.2% reduction in deaths in a Phase 3 clinical study for hospitalized COVID-19 patients at high risk for ARDS. The study also indicated significant reductions in ICU stays, mechanical ventilation duration, and overall hospital days. Veru is seeking emergency use authorization from the FDA and plans to approach Health Canada for expedited review.
Valeo Pharma Inc. (CSE: VPH) announces significant advancements for its asthma treatments, Enerzair Breezehaler and Atectura Breezhaler, with public reimbursement now established in Ontario, Manitoba, and New Brunswick, alongside federal programs covering over 80% of Canadians with chronic asthma. The Ontario listing begins on February 28, 2022. Additionally, private insurance coverage across Canada exceeds 90%. This expansion is a pivotal step in enhancing access to these therapies and supports Valeo's strategy to build a robust respiratory business unit.
Valeo Pharma announced that Hesperco, its flavonoid formulation for immune support, is now available in approximately 300 Loblaws stores across Canada. The product aims to leverage the well-documented immune support properties of hesperidin. Additionally, clinical trial results demonstrated that hesperidin may help reduce COVID-19 symptoms, with a formal publication submitted for review. Valeo Pharma partners with Ingenew Pharma for the development and commercialization of Hesperco, highlighting potential for further studies to explore its benefits in immune management.
Valeo Pharma has secured its first provincial public listing for asthma treatments, Enerzair Breezhaler and Atectura Breezhaler, on Alberta's Drug Benefit list effective November 1, 2021. This achievement marks a significant milestone in expanding access to innovative asthma therapies across Canada. The company also reports 85% private payer health plan coverage nationwide for these medications. Valeo aims to negotiate similar reimbursements in other provinces, enhancing patient access to their treatments.
Valeo Pharma has secured two multi-year agreements with Canada's major Group Purchasing Organizations (GPOs) for its low molecular weight heparin biosimilars, Redesca and Redesca HP, effective from October 1, 2021. These listings will enhance access for over 700 hospitals across five provinces, including Ontario, and include three other specialty hospital products. Valeo's CEO emphasized the competitive nature of the Canadian hospital market while highlighting the extensive reimbursement coverage supporting Redesca's growth.
Valeo Pharma announced a successful negotiation with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding its innovative asthma treatments, Enerzair Breezhaler and Atectura Breezhaler. This agreement aims to establish a framework supporting public drug listings across Canada. Currently, private health plan coverage for these products exceeds 85% in Canada. Valeo's President, Frederic Fasano, expressed optimism that the positive feedback and ongoing clinical trials will expedite public coverage, benefiting asthma patients.
Valeo Pharma Inc. announced that its low molecular weight heparin biosimilars, Redesca™ and Redesca HP™, are now publicly reimbursed in 7 Canadian provinces and territories. Additionally, private payer health plan coverage has reached 70%. Provinces currently covering these products include Alberta, Manitoba, Ontario, New Brunswick, Prince Edward Island, Newfoundland, and the Northwest Territories. Valeo's COO expressed optimism about the product's market impact and ongoing discussions for broader coverage by year-end.
Valeo Pharma Inc (CSE:VPH) (OTCQB:VPHIF) will report its second quarter financial results for the period ending April 30, 2021 on June 29, 2021, after market close. A conference call to discuss these results will take place on June 30, 2021, at 8:30 AM ET. Investors can participate by calling 1-888-664-6392 or 416-764-8659. An audio replay will be available at 1-888-390-0541 using access code (069481#). Valeo is focused on innovative prescription products in areas like respiratory and oncology diseases.
Valeo Pharma has launched its asthma treatments, Enerzair Breezhaler and Atectura Breezhaler, in Canada, entering a $700 million market. Product shipments have commenced, and the recruitment of a national respiratory sales force is well underway. Nelly Komari joins the company as Senior Vice President of Scientific & Medical Affairs, enhancing the team. The new therapies aim to address the needs of approximately 4 million Canadians living with asthma, offering improved symptom control and reduced exacerbation risks.
FAQ
What is the market cap of VALEO PHARMA (VPHIF)?
